Disclosure Of First-Time Adoption [Text Block]

OSE Immunotherapeutics - Filing #2816794

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	160,000 EUR	—	47 890 EUR	—	—	—	21 111 EUR	65 605 EUR	—	150,000 EUR	3 705 EUR	—	—	—	3 597 EUR	7 485 EUR	93,000 EUR	104,000 EUR	65 449 EUR	—	61 364 EUR	—	—	—	100,000 EUR	48 497 EUR	58 536 EUR	148,000 EUR	7 286 EUR	3 001 EUR
Comprehensive income	—	0 EUR	—	16 825 EUR	0 EUR	55,000 EUR	—	—	0 EUR	—	—	16 879 EUR	16 561 EUR	0 EUR	—	—	—	—	—	16 558 EUR	—	0 EUR	4,000 EUR	0 EUR	—	—	—	—	—	—
Profit (loss)	—	—	—	16 850 EUR	—	—	—	—	—	—	—	16 850 EUR	16 555 EUR	—	—	—	—	—	—	16 555 EUR	—	—	—	—	—	—	—	—	—	—